Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03686124 · ClinicalTrials.gov registry record · Phase 1
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
A Phase 1 study of Cancer and Solid Tumor, Adult, sponsored by Immatics US.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 375
- Enrollment target
- 18
- Study locations
NCT03686124: Recruiting Phase 1 study of Cancer and Solid Tumor, Adult, sponsored by Immatics US.
NCT03686124 is a Phase 1 study of Cancer and Solid Tumor, Adult that is actively recruiting participants, run by Immatics US. The registered enrollment target is 375 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (89% lower). The trial reports 18 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03686124, a Phase 1 study of Cancer and Solid Tumor, Adult, is actively recruiting participants, sponsored by Immatics US.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 375 participants
- Enrollment target
- 18
- Study locations
Study Summary
The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).
Primary Outcome
Number of patients with dose-limiting toxicities (DLTs)
Conditions Studied
Interventions
- DRUG Nivolumab
- BIOLOGICAL IMA203 Product
- BIOLOGICAL IMA203 product- flat dose
- BIOLOGICAL IMA203CD8 Product
- DEVICE IMADetect®
Study Locations (18)
Pennsylvania
- University of Pennsylvania, Perelamn Center for Advanced Medicine - Philadelphia
- Fox Chase Cancer Center - Philadelphia
- University of Pittsburgh Medical Center - Pittsburgh
Bavaria
- Klinikum rechts der Isar der Technischen Universität München - Munich
- Klinikum rechts der Isar der Technischen Universität München - Munich
- Universitätsklinikum Würzburg - Würzburg
Other
- Charité Benjamin Franklin - Klinik für Hämatologie und Onkologie - Berlin
- Universitätsklinikum Hamburg-Eppendorf - Hamburg
California
- Stanford Cancer Institute - Stanford
Florida
- University of Miami Hospital and Clinics - Miami
Illinois
- University of Chicago Medical Center - Chicago
Massachusetts
- Massachusetts General Hospital - Boston
Ohio
- Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2019-05-14 |
| Est. Completion | 2032-06 |
| Phase | Phase 1 |
What NCT03686124 shows while recruiting
NCT03686124 is an interventional study that assigns participants to a tested intervention. The registered 375 participants enrollment target is mid-sized for trials with a published cap, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (89% lower).
The record links to 4 conditions, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Nivolumab is the first listed.
NCT03686124 lists 18 locations in 13 states (Pennsylvania, Bavaria, Other).
Frequently Asked Questions
What is clinical trial NCT03686124 about?
NCT03686124 is a clinical study titled "ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors". The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).
What is the current status of trial NCT03686124?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 375 participants. The study started on 2019-05-14. Estimated completion is 2032-06.
What conditions does trial NCT03686124 study?
This clinical trial studies the following conditions: Cancer, Solid Tumor, Adult, Refractory Cancer, Recurrent Cancer.
What interventions are being tested in trial NCT03686124?
The interventions under investigation include: Nivolumab (DRUG), IMA203 Product (BIOLOGICAL), IMA203 product- flat dose (BIOLOGICAL), IMA203CD8 Product (BIOLOGICAL), IMADetect® (DEVICE).
Who is sponsoring clinical trial NCT03686124?
This trial is sponsored by Immatics US, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03686124 being conducted?
This trial has 18 study locations across California, Florida, Illinois, Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03686124's enrollment target sits among peer trials
375 158th of 615 higher than 457 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04059172 · 375 participants · Early Phase 1
Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management
- NCT04134923 · 375 participants
Imaging Biomarkers in Preclinical and Symptomatic AD
- NCT04569747 · 375 participants · Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
- NCT04571658 · 375 participants · NA
NEPTUNE Match Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI